Chronic myeloid leukemia from basics to bedside

Thijsen, S. F. T.; Schuurhuis, G.J.; Oostveen, J. W. Van; Ossenkoppele, Gert J.

doi:10.1038/sj.leu.2401565

Cited by 57 publications

(43 citation statements)

References 331 publications

(232 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The biology of the BCR-ABL oncogene and its intracellular signal transduction pathways have been extensively reviewed [41][42][43][44] and only the key parts will be discussed here ( Figure 1). The BCR-ABL oncoprotein has constitutively expressed tyrosine kinase activity as a result of oligomerization of the coiled coil region of p210 BCR/ABL 45 and deletion of the inhibitory SH3 domain of ABL.…”

Section: Signal Transduction In Chronic Phase CMLmentioning

confidence: 99%

Chronic myelogenous leukemia: mechanisms underlying disease progression

2002

View full text Add to dashboard Cite

Chronic myelogenous leukemia (CML), characterized by the BCR-ABL gene rearrangement, has been extensively studied. Significant progress has been made in the area of BCR-ABLmediated intracellular signaling, which has led to a better understanding of BCR-ABL-mediated clinical features in chronic phase CML. Disease progression and blast crisis CML is associated with characteristic non-random cytogenetic and molecular events. These can be viewed as increased oncogenic activity or loss of tumor suppressor activity. However, what causes transformation and disease progression to blast crisis is only poorly understood. This is in part due to the lack of a good in vivo model of chronic phase CML even though animal models developed over the last few years have started to provide insights into blast crisis development. Thus, additional in vitro and in vivo studies will be needed to provide a complete understanding of the contribution of BCR-ABL and other genes to disease progression and to improve therapeutic approaches for blast crisis CML.

show abstract

Section: Signal Transduction In Chronic Phase CMLmentioning

confidence: 99%

Chronic myelogenous leukemia: mechanisms underlying disease progression

2002

View full text Add to dashboard Cite

show abstract

“…ABL-BCR is expressed in about 60% of patients with CML, but probably lacks any biological function 6 (review, see Ref. 7). The degree of tumor load reduction is an important prognostic factor for patients with CML on therapy.…”

Section: Introductionmentioning

confidence: 99%

Detection and quantification of residual disease in chronic myelogenous leukemia

Hochhaus¹,

Weisser²,

Rosée³

et al. 2000

Leukemia

View full text Add to dashboard Cite

The degree of tumor load reduction after therapy is an important prognostic factor for patients with CML. Conventional metaphase analysis has been considered to be the 'gold standard' for evaluating patient response to treatment but this technique normally requires bone marrow aspiration and is therefore invasive. The frequency of cytogenetic analyses can be considerably reduced if patients are also monitored by molecular methods, which can be performed on peripheral blood specimens.

show abstract

“…The latter two are used preferably, and which to choose depends on the patient's clinical characteristics and the availability of a matched donor. New drugs and new therapeutic strategies are under active investigation for both the chronic and the transformed phase of CML (reviewed in Faderl et al, 1999a;Thijsen et al, 1999). Although they will not be discussed specifically here except for STI 571, a principle by which test selection is made and might be extended to an investigational therapy will be suggested at the end of this section.…”

Section: Laboratory Monitoring Of Therapiesmentioning

confidence: 99%

Chronic myelogenous leukemia: Laboratory diagnosis and monitoring

Wang

Bagg

Pear

et al. 2001

Genes Chromosomes & Cancer

View full text Add to dashboard Cite

Rapid developments have occurred both in laboratory medicine and in therapeutic interventions for the management of patients with chronic myelogenous leukemia (CML). With a wide array of laboratory tests available, selecting the appropriate test for a specific diagnostic or therapeutic setting has become increasingly difficult. In this review, we first discuss, from the point of view of laboratory medicine, the advantages and disadvantages of several commonly used laboratory assays, including cytogenetics, fluorescence in situ hybridization (FISH), and qualitative and quantitative reverse transcriptase-polymerase chain reaction (RT-PCR). We then discuss, from the point of view of clinical care, the test(s) of choice for the most common clinical scenarios, including diagnosis and monitoring of the therapeutic response and minimal residual disease in patients treated with different therapies. The purpose of this review is to help clinicians and laboratory physicians select appropriate tests for the diagnosis and monitoring of CML, with the ultimate goal of improving the cost-effective usage of clinical laboratories and improving patient care.

show abstract

Chronic myeloid leukemia from basics to bedside

Cited by 57 publications

References 331 publications

Chronic myelogenous leukemia: mechanisms underlying disease progression

Chronic myelogenous leukemia: mechanisms underlying disease progression

Detection and quantification of residual disease in chronic myelogenous leukemia

Chronic myelogenous leukemia: Laboratory diagnosis and monitoring

Contact Info

Product

Resources

About